Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer

作者：Jia, Xiao-qing; Hong, Qi; Cheng, Jing-yi; Li, Jian-wei; Wang, Yu-jie; Mo, Miao; Shao, Zhi-min; Shen, Zhen-zhou; Liu, Guang-yu^*

来源：OncoTargets and Therapy, 2015, 8: 549-555.

DOI：10.2147/OTT.S76879

• p53
• breast cancer
• prognosis
• endocrine resistance

Objective: Studies have indicated that p53 protein accumulation exerts an adverse effect on the survival of breast cancer patients; however, the prognostic value of p53 protein accumulation for aromatase inhibitor (AI) resistance in ER-positive breast cancer is uncertain. @@@ Methods: The expression level of p53 protein was detected by immunohistochemistry in primary early-stage ER-positive breast tumor specimens from 293 postmenopausal breast cancer patients who received first-line AI treatment (letrozole, anastrozole, or exemestane) until relapse, and analysis was performed to determine whether expression of p53 protein affected the response to endocrine therapy. @@@ Results: Of the 293 invasive ductal carcinomas, 65.4% were positive for p53 protein expression. All patients received AI therapy as first-line treatment until relapse. The 5-year disease-free survival rates in p53-positive and p53-negative patients were 78% and 89%, respectively. Patients with primary breast tumors that had p53 protein accumulation showed significantly more resistance to AI treatment (hazard ratio=1.729, 95% confidence interval=1.038-2.880, P=0.035). @@@ Conclusion: This study demonstrated that p53 protein accumulation was helpful in choosing patients who may benefit from AI treatment and is a prognostic marker in ER-positive early-stage breast cancer.

• 出版日期2015
• 单位复旦大学